Nab-Paclitaxel, Pembrolizumab Combo Active in Advanced Urothelial Cancer
Overall response rate 50 percent among 36 patients with platinum-refractory or cisplatin-ineligible advanced urothelial cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.